{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:50:26Z","timestamp":1779238226802,"version":"3.51.4"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T00:00:00Z","timestamp":1480464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T00:00:00Z","timestamp":1480464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1038\/leu.2016.367","type":"journal-article","created":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T07:41:44Z","timestamp":1480491704000},"page":"543-554","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Novel targets in the treatment of chronic graft-versus-host disease"],"prefix":"10.1038","volume":"31","author":[{"given":"A","family":"Im","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F T","family":"Hakim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S Z","family":"Pavletic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,30]]},"reference":[{"key":"BFleu2016367_CR1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/01.moh.0000245689.47333.ff","volume":"13","author":"K Baird","year":"2006","unstructured":"Baird K, Pavletic SZ . Chronic graft versus host disease. Curr Opin Hematol 2006; 13: 426\u2013435.","journal-title":"Curr Opin Hematol"},{"key":"BFleu2016367_CR2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/bbmt.2003.50026","volume":"9","author":"SJ Lee","year":"2003","unstructured":"Lee SJ, Vogelsang G, Flowers ME . Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 215\u2013233.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2016367_CR3","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bbmt.2014.10.021","volume":"21","author":"S Arai","year":"2015","unstructured":"Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 2015; 21: 266\u2013274.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2016367_CR4","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1200\/JCO.2010.33.7212","volume":"29","author":"JR Wingard","year":"2011","unstructured":"Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011; 29: 2230\u20132239.","journal-title":"J Clin Oncol"},{"key":"BFleu2016367_CR5","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2009.25.6693","volume":"28","author":"PJ Martin","year":"2010","unstructured":"Martin PJ, Counts GW Jr., Appelbaum FR, Lee SJ, Sanders JE, Deeg HJ et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol 2010; 28: 1011\u20131016.","journal-title":"J Clin Oncol"},{"key":"BFleu2016367_CR6","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-11-319509","volume":"117","author":"J Pidala","year":"2011","unstructured":"Pidala J, Kurland B, Chai X, Majhail N, Weisdorf DJ, Pavletic S et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood 2011; 117: 4651\u20134657.","journal-title":"Blood"},{"key":"BFleu2016367_CR7","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood-2014-01-514752","volume":"124","author":"G Socie","year":"2014","unstructured":"Socie G, Ritz J . Current issues in chronic graft-versus-host disease. Blood 2014; 124: 374\u2013384.","journal-title":"Blood"},{"key":"BFleu2016367_CR8","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nri3212","volume":"12","author":"BR Blazar","year":"2012","unstructured":"Blazar BR, Murphy WJ, Abedi M . Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 2012; 12: 443\u2013458.","journal-title":"Nat Rev Immunol"},{"key":"BFleu2016367_CR9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bbmt.2014.10.029","volume":"21","author":"S Sarantopoulos","year":"2015","unstructured":"Sarantopoulos S, Blazar BR, Cutler C, Ritz J . B cells in chronic graft-versus-host disease. Biol Blood Marrow Transplant 2015; 21: 16\u201323.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2016367_CR10","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1182\/blood-2015-09-668145","volume":"127","author":"H Jin","year":"2016","unstructured":"Jin H, Ni X, Deng R, Song Q, Young J, Cassady K et al. Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice. Blood 2016; 127: 2249\u20132260.","journal-title":"Blood"},{"key":"BFleu2016367_CR11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood-2016-02-702852","volume":"128","author":"J Koreth","year":"2016","unstructured":"Koreth J, Kim HT, Jones KT, Lange PB, Reynolds CG, Chammas MJ et al. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood 2016; 128: 130\u2013137.","journal-title":"Blood"},{"key":"BFleu2016367_CR12","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","volume":"365","author":"J Koreth","year":"2011","unstructured":"Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP 3rd et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011; 365: 2055\u20132066.","journal-title":"N Engl J Med"},{"key":"BFleu2016367_CR13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5045\/kjh.2011.46.3.153","volume":"46","author":"PJ Martin","year":"2011","unstructured":"Martin PJ, Inamoto Y, Carpenter PA, Lee SJ, Flowers ME . Treatment of chronic graft-versus-host disease: Past, present and future. Korean J Hematol 2011; 46: 153\u2013163.","journal-title":"Korean J Hematol"},{"key":"BFleu2016367_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbmt.2010.05.011","volume":"17","author":"D Wolff","year":"2011","unstructured":"Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2011; 17: 1\u201317.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2016367_CR15","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2004-01-0200","volume":"104","author":"BL Stewart","year":"2004","unstructured":"Stewart BL, Storer B, Storek J, Deeg HJ, Storb R, Hansen JA et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 2004; 104: 3501\u20133506.","journal-title":"Blood"},{"key":"BFleu2016367_CR16","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.bbmt.2007.12.002","volume":"14","author":"YW Chu","year":"2008","unstructured":"Chu YW, Gress RE . Murine models of chronic graft-versus-host disease: insights and unresolved issues. Biol Blood Marrow Transplant 2008; 14: 365\u2013378.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2016367_CR17","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/blood-2016-02-699082","volume":"127","author":"R Zeiser","year":"2016","unstructured":"Zeiser R, Blazar BR . Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation? Blood 2016; 127: 3117\u20133126.","journal-title":"Blood"},{"key":"BFleu2016367_CR18","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1182\/blood-2011-03-344390","volume":"118","author":"S Arai","year":"2011","unstructured":"Arai S, Jagasia M, Storer B, Chai X, Pidala J, Cutler C et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood 2011; 118: 4242\u20134249.","journal-title":"Blood"},{"key":"BFleu2016367_CR19","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.bbmt.2013.01.013","volume":"19","author":"K Baird","year":"2013","unstructured":"Baird K, Steinberg SM, Grkovic L, Pulanic D, Cowen EW, Mitchell SA et al. National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis. Biol Blood Marrow Transplant 2013; 19: 632\u2013639.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2016367_CR20","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. the 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant 2015; 21: 389\u2013401, e1.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2016367_CR21","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","volume":"21","author":"SJ Lee","year":"2015","unstructured":"Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. the 2014 response criteria working group report. Biol Blood Marrow Transplant 2015; 21: 984\u2013999.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2016367_CR22","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.bbmt.2015.05.004","volume":"21","author":"PJ Martin","year":"2015","unstructured":"Martin PJ, Lee SJ, Przepiorka D, Horowitz MM, Koreth J, Vogelsang GB et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: VI. the 2014 clinical trial design working group report. Biol Blood Marrow Transplant 2015; 21: 1343\u20131359.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2016367_CR23","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/blood-2015-10-678706","volume":"127","author":"R Flynn","year":"2016","unstructured":"Flynn R, Paz K, Du J, Reichenbach DK, Taylor PA, Panoskaltsis-Mortari A et al. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood 2016; 127: 2144\u20132154.","journal-title":"Blood"},{"key":"BFleu2016367_CR24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1158\/1078-0432.CCR-10-1198","volume":"17","author":"I Tawara","year":"2011","unstructured":"Tawara I, Koyama M, Liu C, Toubai T, Thomas D, Evers R et al. Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin Cancer Res 2011; 17: 77\u201388.","journal-title":"Clin Cancer Res"},{"key":"BFleu2016367_CR25","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/ni.1741","volume":"10","author":"A Doreau","year":"2009","unstructured":"Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009; 10: 778\u2013785.","journal-title":"Nat Immunol"},{"key":"BFleu2016367_CR26","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.ajpath.2012.07.017","volume":"181","author":"P Zerr","year":"2012","unstructured":"Zerr P, Distler A, Palumbo-Zerr K, Tomcik M, Vollath S, Dees C et al. Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease. Am J Pathol 2012; 181: 1672\u20131680.","journal-title":"Am J Pathol"},{"key":"BFleu2016367_CR27","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3325\/cmj.2016.57.247","volume":"57","author":"I Sanchez-Ortega","year":"2016","unstructured":"Sanchez-Ortega I, Parody R, Servitje O, Muniesa C, Arnan M, Patino B et al. Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease. Croatian Med J 2016; 57: 247\u2013254.","journal-title":"Croatian Med J"},{"key":"BFleu2016367_CR28","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/bmt.2010.195","volume":"45","author":"JY Weng","year":"2010","unstructured":"Weng JY, Du X, Geng SX, Peng YW, Wang Z, Lu ZS et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant 2010; 45: 1732\u20131740.","journal-title":"Bone Marrow Transplant"},{"key":"BFleu2016367_CR29","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1200\/JCO.2015.65.3642","volume":"34","author":"L Gao","year":"2016","unstructured":"Gao L, Zhang Y, Hu B, Liu J, Kong P, Lou S et al. Phase II multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord-derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem-cell transplantation. J Clin Oncol 2016; 34: 2843\u20132850.","journal-title":"J Clin Oncol"},{"key":"BFleu2016367_CR30","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1182\/blood-2015-06-653667","volume":"127","author":"CG Brunstein","year":"2016","unstructured":"Brunstein CG, Miller JS, McKenna DH, Hippen KL, DeFor TE, Sumstad D et al. Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood 2016; 127: 1044\u20131051.","journal-title":"Blood"},{"key":"BFleu2016367_CR31","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1172\/JCI81229","volume":"125","author":"M Bleakley","year":"2015","unstructured":"Bleakley M, Heimfeld S, Loeb KR, Jones LA, Chaney C, Seropian S et al. Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts. J Clin Invest 2015; 125: 2677\u20132689.","journal-title":"J Clin Invest"},{"key":"BFleu2016367_CR32","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/nrclinonc.2015.128","volume":"13","author":"CG Kanakry","year":"2016","unstructured":"Kanakry CG, Fuchs EJ, Luznik L . Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol 2016; 13: 10\u201324.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFleu2016367_CR33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/imr.12418","volume":"271","author":"MS Chaudhry","year":"2016","unstructured":"Chaudhry MS, Velardi E, Dudakov JA, van den Brink MR . Thymus: the next (re)generation. Immunol Rev 2016; 271: 56\u201371.","journal-title":"Immunol Rev"},{"key":"BFleu2016367_CR34","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi K, Laurence A, O'Shea JJ . Janus kinases in immune cell signaling. Immunol Rev 2009; 228: 273\u2013287.","journal-title":"Immunol Rev"},{"key":"BFleu2016367_CR35","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMra1202117","volume":"368","author":"JJ O'Shea","year":"2013","unstructured":"O'Shea JJ, Holland SM, Staudt LM . JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 2013; 368: 161\u2013170.","journal-title":"N Engl J Med"},{"key":"BFleu2016367_CR36","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799\u2013807.","journal-title":"N Engl J Med"},{"key":"BFleu2016367_CR37","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1182\/blood-2012-01-403196","volume":"120","author":"J Choi","year":"2012","unstructured":"Choi J, Ziga ED, Ritchey J, Collins L, Prior JL, Cooper ML et al. IFNgammaR signaling mediates alloreactive T-cell trafficking and GVHD. Blood 2012; 120: 4093\u20134103.","journal-title":"Blood"},{"key":"BFleu2016367_CR38","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.4049\/jimmunol.1601054","volume":"197","author":"FT Hakim","year":"2016","unstructured":"Hakim FT, Memon S, Jin P, Imanguli MM, Wang H, Rehman N et al. Upregulation of IFN-inducible and damage-response pathways in chronic graft-versus-host disease. J Immunol 2016; 197: 3490\u20133503.","journal-title":"J Immunol"},{"key":"BFleu2016367_CR39","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood-2013-03-484642","volume":"122","author":"A Heine","year":"2013","unstructured":"Heine A, Held SA, Daecke SN, Wallner S, Yajnanarayana SP, Kurts C et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 2013; 122: 1192\u20131202.","journal-title":"Blood"},{"key":"BFleu2016367_CR40","doi-asserted-by":"crossref","first-page":"e109799","DOI":"10.1371\/journal.pone.0109799","volume":"9","author":"J Choi","year":"2014","unstructured":"Choi J, Cooper ML, Alahmari B, Ritchey J, Collins L, Holt M et al. Pharmacologic blockade of JAK1\/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect. PloS One 2014; 9: e109799.","journal-title":"PloS One"},{"key":"BFleu2016367_CR41","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","volume":"123","author":"S Spoerl","year":"2014","unstructured":"Spoerl S, Mathew NR, Bscheider M, Schmitt-Graeff A, Chen S, Mueller T et al. Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease. Blood 2014; 123: 3832\u20133842.","journal-title":"Blood"},{"key":"BFleu2016367_CR42","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1158\/1078-0432.CCR-14-2758","volume":"21","author":"C Carniti","year":"2015","unstructured":"Carniti C, Gimondi S, Vendramin A, Recordati C, Confalonieri D, Bermema A et al. Pharmacologic Inhibition of JAK1\/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects. Clin Cancer Res 2015; 21: 3740\u20133749.","journal-title":"Clin Cancer Res"},{"key":"BFleu2016367_CR43","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","volume":"29","author":"R Zeiser","year":"2015","unstructured":"Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 2015; 29: 2062\u20132068.","journal-title":"Leukemia"},{"key":"BFleu2016367_CR44","doi-asserted-by":"crossref","unstructured":"Khoury HJ, Kota V, Arellano M, Bauer SL, Jillela AP, Langston A et al. Ruxolitinib as sparing agent for steroid-dependent chronic graft-versus-host disease. Blood 2015; 126: abstract 1938.","DOI":"10.1182\/blood.V126.23.1938.1938"},{"key":"BFleu2016367_CR45","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1073\/pnas.0401563101","volume":"101","author":"K Sun","year":"2004","unstructured":"Sun K, Welniak LA, Panoskaltsis-Mortari A, O'Shaughnessy MJ, Liu H, Barao I et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 2004; 101: 8120\u20138125.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2016367_CR46","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1182\/blood-2005-05-2118","volume":"107","author":"B Blanco","year":"2006","unstructured":"Blanco B, Perez-Simon JA, Sanchez-Abarca LI, Carvajal-Vergara X, Mateos J, Vidriales B et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006; 107: 3575\u20133583.","journal-title":"Blood"},{"key":"BFleu2016367_CR47","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1097\/TP.0b013e3181bd7b3a","volume":"88","author":"JS Kim","year":"2009","unstructured":"Kim JS, Lee JI, Shin JY, Kim SY, Shin JS, Lim JH et al. Bortezomib can suppress activation of rapamycin-resistant memory T cells without affecting regulatory T-cell viability in non-human primates. Transplantation 2009; 88: 1349\u20131359.","journal-title":"Transplantation"},{"key":"BFleu2016367_CR48","first-page":"1677","volume":"124","author":"CC Pai","year":"2014","unstructured":"Pai CC, Chen M, Mirsoian A, Grossenbacher SK, Tellez J, Ames E et al. Treatment of chronic graft-versus-host disease with bortezomib. Blood 2014; 124: 1677\u20131688.","journal-title":"Blood"},{"key":"BFleu2016367_CR49","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.bbmt.2014.06.040","volume":"20","author":"AF Herrera","year":"2014","unstructured":"Herrera AF, Kim HT, Bindra B, Jones KT, Alyea EP 3rd, Armand P et al. A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2014; 20: 1737\u20131743.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2016367_CR50","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.bbmt.2015.05.027","volume":"21","author":"J Koreth","year":"2015","unstructured":"Koreth J, Kim HT, Lange PB, Bindra B, Reynolds CG, Chammas MJ et al. A bortezomib-based regimen offers promising survival and graft-versus-host disease prophylaxis in myeloablative HLA-mismatched and unrelated donor transplantation: a phase II trial. Biol Blood Marrow Transplant 2015; 21: 1907\u20131913.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2016367_CR51","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1200\/JCO.2012.42.0984","volume":"30","author":"J Koreth","year":"2012","unstructured":"Koreth J, Stevenson KE, Kim HT, McDonough SM, Bindra B, Armand P et al. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol 2012; 30: 3202\u20133208.","journal-title":"J Clin Oncol"},{"key":"BFleu2016367_CR52","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015; 372: 142\u2013152.","journal-title":"N Engl J Med"},{"key":"BFleu2016367_CR53","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 2016; 374: 1621\u20131634.","journal-title":"N Engl J Med"},{"key":"BFleu2016367_CR54","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.tips.2010.11.002","volume":"32","author":"H Chi","year":"2011","unstructured":"Chi H . Sphingosine-1-phosphate and immune regulation: trafficking and beyond. Trends Pharmacol Sci 2011; 32: 16\u201324.","journal-title":"Trends Pharmacol Sci"},{"key":"BFleu2016367_CR55","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.4049\/jimmunol.164.11.5761","volume":"164","author":"DD Pinschewer","year":"2000","unstructured":"Pinschewer DD, Ochsenbein AF, Odermatt B, Brinkmann V, Hengartner H, Zinkernagel RM . FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol 2000; 164: 5761\u20135770.","journal-title":"J Immunol"},{"key":"BFleu2016367_CR56","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1172\/JCI200316950","volume":"111","author":"YM Kim","year":"2003","unstructured":"Kim YM, Sachs T, Asavaroengchai W, Bronson R, Sykes M . Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. The J Clin Invest 2003; 111: 659\u2013669.","journal-title":"The J Clin Invest"},{"key":"BFleu2016367_CR57","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/art.37933","volume":"65","author":"DL Huu","year":"2013","unstructured":"Huu DL, Matsushita T, Jin G, Hamaguchi Y, Hasegawa M, Takehara K et al. FTY720 ameliorates murine sclerodermatous chronic graft-versus-host disease by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin. Arthritis Rheum 2013; 65: 1624\u20131635.","journal-title":"Arthritis Rheum"},{"key":"BFleu2016367_CR58","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1182\/blood-2007-05-087940","volume":"110","author":"PA Taylor","year":"2007","unstructured":"Taylor PA, Ehrhardt MJ, Lees CJ, Tolar J, Weigel BJ, Panoskaltsis-Mortari A et al. Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD). Blood 2007; 110: 3480\u20133488.","journal-title":"Blood"},{"key":"BFleu2016367_CR59","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/2040622315617354","volume":"7","author":"D D'Ambrosio","year":"2016","unstructured":"D'Ambrosio D, Freedman MS, Prinz J . Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases. Ther Adv Chronic Dis 2016; 7: 18\u201333.","journal-title":"Ther Adv Chronic Dis"},{"key":"BFleu2016367_CR60","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/ni.1939","volume":"11","author":"G Liu","year":"2010","unstructured":"Liu G, Yang K, Burns S, Shrestha S, Chi H . The S1P(1)-mTOR axis directs the reciprocal differentiation of T(H)1 and T(reg) cells. Nat Immunol 2010; 11: 1047\u20131056.","journal-title":"Nat Immunol"},{"key":"BFleu2016367_CR61","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1136\/jnnp-2013-307282","volume":"85","author":"T Olsson","year":"2014","unstructured":"Olsson T, Boster A, Fernandez O, Freedman MS, Pozzilli C, Bach D et al. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry 2014; 85: 1198\u20131208.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFleu2016367_CR62","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1182\/blood.V83.12.3815.3815","volume":"83","author":"BR Blazar","year":"1994","unstructured":"Blazar BR, Taylor PA, Linsley PS, Vallera DA . In vivo blockade of CD28\/CTLA4: B7\/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood 1994; 83: 3815\u20133825.","journal-title":"Blood"},{"key":"BFleu2016367_CR63","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.4049\/jimmunol.157.9.4258","volume":"157","author":"CS Via","year":"1996","unstructured":"Via CS, Rus V, Nguyen P, Linsley P, Gause WC . Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD. J Immunol 1996; 157: 4258\u20134267.","journal-title":"J Immunol"},{"key":"BFleu2016367_CR64","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJM199906033402202","volume":"340","author":"EC Guinan","year":"1999","unstructured":"Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 1999; 340: 1704\u20131714.","journal-title":"N Engl J Med"},{"key":"BFleu2016367_CR65","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.bbmt.2013.09.003","volume":"19","author":"DT Koura","year":"2013","unstructured":"Koura DT, Horan JT, Langston AA, Qayed M, Mehta A, Khoury HJ et al. In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial. Biol Blood Marrow Transplant 2013; 19: 1638\u20131649.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2016367_CR66","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1182\/blood-2008-10-161638","volume":"114","author":"A Shimabukuro-Vornhagen","year":"2009","unstructured":"Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, von Bergwelt-Baildon MS . The role of B cells in the pathogenesis of graft-versus-host disease. Blood 2009; 114: 4919\u20134927.","journal-title":"Blood"},{"key":"BFleu2016367_CR67","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2011-07-364414","volume":"119","author":"M Srinivasan","year":"2012","unstructured":"Srinivasan M, Flynn R, Price A, Ranger A, Browning JL, Taylor PA et al. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood 2012; 119: 1570\u20131580.","journal-title":"Blood"},{"key":"BFleu2016367_CR68","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2004-09-3660","volume":"105","author":"DB Miklos","year":"2005","unstructured":"Miklos DB, Kim HT, Miller KH, Guo L, Zorn E, Lee SJ et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005; 105: 2973\u20132978.","journal-title":"Blood"},{"key":"BFleu2016367_CR69","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1158\/1078-0432.CCR-07-1290","volume":"13","author":"S Sarantopoulos","year":"2007","unstructured":"Sarantopoulos S, Stevenson KE, Kim HT, Bhuiya NS, Cutler CS, Soiffer RJ et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res 2007; 13: 6107\u20136114.","journal-title":"Clin Cancer Res"},{"key":"BFleu2016367_CR70","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2008-09-177840","volume":"113","author":"S Sarantopoulos","year":"2009","unstructured":"Sarantopoulos S, Stevenson KE, Kim HT, Cutler CS, Bhuiya NS, Schowalter M et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 2009; 113: 3865\u20133874.","journal-title":"Blood"},{"key":"BFleu2016367_CR71","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1182\/blood-2013-10-533562","volume":"123","author":"JL Allen","year":"2014","unstructured":"Allen JL, Tata PV, Fore MS, Wooten J, Rudra S, Deal AM et al. Increased BCR responsiveness in B cells from patients with chronic GVHD. Blood 2014; 123: 2108\u20132115.","journal-title":"Blood"},{"key":"BFleu2016367_CR72","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1182\/blood-2014-08-595470","volume":"125","author":"R Flynn","year":"2015","unstructured":"Flynn R, Allen JL, Luznik L, MacDonald KP, Paz K, Alexander KA et al. Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood 2015; 125: 4085\u20134094.","journal-title":"Blood"},{"key":"BFleu2016367_CR73","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2014-12-567834","volume":"125","author":"S Sarantopoulos","year":"2015","unstructured":"Sarantopoulos S, Ritz J . Aberrant B-cell homeostasis in chronic GVHD. Blood 2015; 125: 1703\u20131707.","journal-title":"Blood"},{"key":"BFleu2016367_CR74","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s12185-011-0855-2","volume":"93","author":"MA Kharfan-Dabaja","year":"2011","unstructured":"Kharfan-Dabaja MA, Cutler CS . Rituximab for prevention and treatment of graft-versus-host disease. Int J Hematol 2011; 93: 578\u2013585.","journal-title":"Int J Hematol"},{"key":"BFleu2016367_CR75","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1158\/1078-0432.CCR-15-1443","volume":"22","author":"S Arai","year":"2016","unstructured":"Arai S, Pidala J, Pusic I, Chai X, Jaglowski S, Khera N et al. A randomized phase II crossover study of imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation. Clin Cancer Res 2016; 22: 319\u2013327.","journal-title":"Clin Cancer Res"},{"key":"BFleu2016367_CR76","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1073\/pnas.1222900110","volume":"110","author":"B Sahaf","year":"2013","unstructured":"Sahaf B, Yang Y, Arai S, Herzenberg LA, Herzenberg LA, Miklos DB . H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease. Proc Natl Acad Sci USA 2013; 110: 3005\u20133010.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2016367_CR77","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1182\/blood-2013-04-495895","volume":"122","author":"C Cutler","year":"2013","unstructured":"Cutler C, Kim HT, Bindra B, Sarantopoulos S, Ho VT, Chen YB et al. Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood 2013; 122: 1510\u20131517.","journal-title":"Blood"},{"key":"BFleu2016367_CR78","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.1182\/blood-2011-12-395970","volume":"119","author":"S Arai","year":"2012","unstructured":"Arai S, Sahaf B, Narasimhan B, Chen GL, Jones CD, Lowsky R et al. Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood 2012; 119: 6145\u20136154.","journal-title":"Blood"},{"key":"BFleu2016367_CR79","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.bbmt.2015.03.014","volume":"21","author":"J Pidala","year":"2015","unstructured":"Pidala J, Kim J, Betts BC, Alsina M, Ayala E, Fernandez HF et al. Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results. Biol Blood Marrow Transplant 2015; 21: 1074\u20131082.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2016367_CR80","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1172\/JCI75328","volume":"124","author":"JA Dubovsky","year":"2014","unstructured":"Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest 2014; 124: 4867\u20134876.","journal-title":"J Clin Invest"},{"key":"BFleu2016367_CR81","doi-asserted-by":"crossref","first-page":"e0137641","DOI":"10.1371\/journal.pone.0137641","volume":"10","author":"SD Schutt","year":"2015","unstructured":"Schutt SD, Fu J, Nguyen H, Bastian D, Heinrichs J, Wu Y et al. Inhibition of BTK and ITK with ibrutinib is effective in the prevention of chronic graft-versus-host disease in mice. PloS One 2015; 10: e0137641.","journal-title":"PloS One"},{"issue":"suppl","key":"BFleu2016367_CR82","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1200\/jco.2015.33.15_suppl.7024","volume":"33","author":"DB Miklos","year":"2015","unstructured":"Miklos DB, Arora M, Cutler CS, Nakamura R, Juretic M, Li Y et al. A multicenter open-label phase 1b\/2 study of ibrutinib in steroid dependent or refractory chronic graft versus host disease. J Clin Oncol 2015; 33 (suppl): 7024 (abstract 7024).","journal-title":"J Clin Oncol"},{"key":"BFleu2016367_CR83","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1038\/bmt.2015.228","volume":"51","author":"D Miklos","year":"2016","unstructured":"Miklos D, Cutler C, Arora M, Walker E, Jagasia M, Nakamura R et al. Multicenter open-label phase 1b\/2 study of ibrutinib in steroid-depenedent\/refractory chronic graft versus host disease. Bone Marrow Transplant 2016; 51: S176 (abstract P124).","journal-title":"Bone Marrow Transplant"},{"key":"BFleu2016367_CR84","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jdermsci.2014.02.008","volume":"74","author":"D Le Huu","year":"2014","unstructured":"Le Huu D, Kimura H, Date M, Hamaguchi Y, Hasegawa M, Hau KT et al. Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease. J Dermatol Sci 2014; 74: 214\u2013221.","journal-title":"J Dermatol Sci"},{"issue":"1 Suppl","key":"BFleu2016367_CR85","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/j.bbmt.2009.11.002","volume":"16","author":"JW Chien","year":"2010","unstructured":"Chien JW, Duncan S, Williams KM, Pavletic SZ . Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2010; 16 (1 Suppl): S106\u2013S114.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2016367_CR86","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.4049\/jimmunol.157.9.4194","volume":"157","author":"B DiGiovine","year":"1996","unstructured":"DiGiovine B, Lynch JP 3rd, Martinez FJ, Flint A, Whyte RI, Iannettoni MD et al. Bronchoalveolar lavage neutrophilia is associated with obliterative bronchiolitis after lung transplantation: role of IL-8. J Immunol 1996; 157: 4194\u20134202.","journal-title":"J Immunol"},{"key":"BFleu2016367_CR87","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1378\/chest.115.2.403","volume":"115","author":"JA Henke","year":"1999","unstructured":"Henke JA, Golden JA, Yelin EH, Keith FA, Blanc PD . Persistent increases of BAL neutrophils as a predictor of mortality following lung transplant. Chest 1999; 115: 403\u2013409.","journal-title":"Chest"},{"issue":"5 Pt 1","key":"BFleu2016367_CR88","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1164\/ajrccm.160.5.9902012","volume":"160","author":"J Hirsch","year":"1999","unstructured":"Hirsch J, Elssner A, Mazur G, Maier KL, Bittmann I, Behr J et al. Bronchiolitis obliterans syndrome after (heart-)lung transplantation. impaired antiprotease defense and increased oxidant activity. Am J Respiratory Crit Care Med 1999; 160 (5 Pt 1): 1640\u20131646.","journal-title":"Am J Respiratory Crit Care Med"},{"key":"BFleu2016367_CR89","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/ajt.12091","volume":"13","author":"VE Kennedy","year":"2013","unstructured":"Kennedy VE, Todd JL, Palmer SM . Bronchoalveolar lavage as a tool to predict, diagnose and understand bronchiolitis obliterans syndrome. Am J Transplant 2013; 13: 552\u2013561.","journal-title":"Am J Transplant"},{"key":"BFleu2016367_CR90","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1124\/jpet.111.182139","volume":"339","author":"T Stevens","year":"2011","unstructured":"Stevens T, Ekholm K, Granse M, Lindahl M, Kozma V, Jungar C et al. AZD9668: pharmacological characterization of a novel oral inhibitor of neutrophil elastase. J Pharmacol Exp Ther 2011; 339: 313\u2013320.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFleu2016367_CR91","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1183\/09031936.00194611","volume":"40","author":"JS Elborn","year":"2012","unstructured":"Elborn JS, Perrett J, Forsman-Semb K, Marks-Konczalik J, Gunawardena K, Entwistle N . Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis. Eur Respir J 2012; 40: 969\u2013976.","journal-title":"Eur Respir J"},{"key":"BFleu2016367_CR92","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.rmed.2011.10.020","volume":"106","author":"P Kuna","year":"2012","unstructured":"Kuna P, Jenkins M, O'Brien CD, Fahy WA . AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide\/formoterol in patients with COPD. Respir Med 2012; 106: 531\u2013539.","journal-title":"Respir Med"},{"key":"BFleu2016367_CR93","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.rmed.2012.12.009","volume":"107","author":"R Stockley","year":"2013","unstructured":"Stockley R, De Soyza A, Gunawardena K, Perrett J, Forsman-Semb K, Entwistle N et al. Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis. Respir Med 2013; 107: 524\u2013533.","journal-title":"Respir Med"},{"key":"BFleu2016367_CR94","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1126\/science.276.5313.817","volume":"276","author":"AE Oro","year":"1997","unstructured":"Oro AE, Higgins KM, Hu Z, Bonifas JM, Epstein EH Jr, Scott MP . Basal cell carcinomas in mice overexpressing sonic hedgehog. Science 1997; 276: 817\u2013821.","journal-title":"Science"},{"key":"BFleu2016367_CR95","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/annrheumdis-2011-200883","volume":"71","author":"A Horn","year":"2012","unstructured":"Horn A, Kireva T, Palumbo-Zerr K, Dees C, Tomcik M, Cordazzo C et al. Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis. Ann Rheum Dis 2012; 71: 785\u2013789.","journal-title":"Ann Rheum Dis"},{"key":"BFleu2016367_CR96","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1182\/blood-2012-01-403428","volume":"120","author":"P Zerr","year":"2012","unstructured":"Zerr P, Palumbo-Zerr K, Distler A, Tomcik M, Vollath S, Munoz LE et al. Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. Blood 2012; 120: 2909\u20132917.","journal-title":"Blood"},{"key":"BFleu2016367_CR97","first-page":"86","volume":"2","author":"NJ Chao","year":"1996","unstructured":"Chao NJ, Parker PM, Niland JC, Wong RM, Dagis A, Long GD et al. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. Biol Blood Marrow Transplant 1996; 2: 86\u201392.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2016367_CR98","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1182\/blood.V96.12.3995","volume":"96","author":"S Koc","year":"2000","unstructured":"Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood 2000; 96: 3995\u20133996.","journal-title":"Blood"},{"key":"BFleu2016367_CR99","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2015-07-567958","volume":"126","author":"EC Fink","year":"2015","unstructured":"Fink EC, Ebert BL . The novel mechanism of lenalidomide activity. Blood 2015; 126: 2366\u20132369.","journal-title":"Blood"},{"key":"BFleu2016367_CR100","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/ni1500","volume":"8","author":"A Brustle","year":"2007","unstructured":"Brustle A, Heink S, Huber M, Rosenplanter C, Stadelmann C, Yu P et al. The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nat Immunol 2007; 8: 958\u2013966.","journal-title":"Nat Immunol"},{"key":"BFleu2016367_CR101","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.bbmt.2015.01.003","volume":"21","author":"S Paczesny","year":"2015","unstructured":"Paczesny S, Hakim FT, Pidala J, Cooke KR, Lathrop J, Griffith LM et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. the 2014 biomarker working group report. Biol Blood Marrow Transplant 2015; 21: 780\u2013792.","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2016367.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2016367","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2016367.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T03:38:45Z","timestamp":1692589125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2016367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,30]]},"references-count":101,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["BFleu2016367"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.367","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,30]]},"assertion":[{"value":"5 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}